Long-term 52-week results of PALACE 3, a phase 3, randomized controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Fecha de publicación
2014Título de revista
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
Tipo de contenido
Publicación de congreso
![](/xmlui/themes/Mirage2//images/final_lines.png)